Patents by Inventor Edward S. Inamine
Edward S. Inamine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5290772Abstract: Described is a process for producing an immunosuppressant, "demethimmunomycin" (L-683,7411) a C-31 demethylated analog of L-683,590 under fermentation conditions utilizing the microorganism, Actinoplanacete sp, (Merck Culture Collection MA 6559) ATCC No. 53771. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.Type: GrantFiled: June 16, 1992Date of Patent: March 1, 1994Assignee: Merck & Co., Inc.Inventors: Edward S. Inamine, Shieh-Shung T. Chen, Byron H. Arison, Linda S. Wicker
-
Patent number: 5268370Abstract: Described is a new immunosuppressant, L-683,519, a monodemethylated rearranged derivative of L-679,934, (FK-506) produced under fermentation conditions utilizing the microorganism, unidentified Actinomycete (Merck Culture Collection MA 6474) ATCC No. 53828. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.Type: GrantFiled: April 22, 1992Date of Patent: December 7, 1993Assignee: Merck & Co., Inc.Inventors: Byron H. Arison, Edward S. Inamine, Shieh-Shung T. Chen, Linda S. Wicker
-
Patent number: 5252612Abstract: Described is a new immunosuppressant, L-683,756, a bisdemethylated, ring rearranged derivative of L-683,590, produced under fermentation conditions utilizing the microorganism, Actinoplanacete sp. (Merck Culture Collection MA 6559) ATCC No. 53771. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.Type: GrantFiled: June 24, 1992Date of Patent: October 12, 1993Assignee: Merck & Co., Inc.Inventors: Byron H. Arison, Edward S. Inamine, Shieh-Shung T. Chen, Linda S. Wicker
-
Patent number: 5250422Abstract: Incubation of 13.beta.-hydroxy ivermectin aglycone with a species of Bacillus subtilis or the incubation of 13-deoxy ivermectin aglycone with a mixed culture of a species of Bacillus subtilis and of Streptomyces griseus results in the production of 13-.beta. ivermectin monoglucopyranoside as the major product and of 5-.beta. ivermectin monoglucopyranoside as the minor product.Type: GrantFiled: May 11, 1992Date of Patent: October 5, 1993Assignee: Merck & Co., Inc.Inventors: Brian R. Petuch, Edward S. Inamine, Shieh-Shung T. Chen, Raymond F. White, Byron H. Arison
-
Patent number: 5202258Abstract: Described is a new microorganism, Actinoplanacete sp., (Merck Culture Collection MA 6559) ATCC No. 53771. The microorganism acts as a demethylating agent and can produce the new immunosuppressants, "demethomycin" (L-682,993) a C-31 demethylated analog of L-679,934, and "demethimmunomycin" (L-683,742) a C-31 demethylated analog of L-683,590, under novel fermentation conditions. These macrolide immunosuppressants are useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.Type: GrantFiled: March 9, 1992Date of Patent: April 13, 1993Assignee: Merck & Co., Inc.Inventors: Shieh-Shung T. Chen, Byron H. Arison, George M. Garrity, Edward S. Inamine, Sagrario Mochales, Linda S. Wicker
-
Patent number: 5116870Abstract: Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors are useful as antihypercholesterolemic agents and are represented by the following general structural formula (II): ##STR1##Type: GrantFiled: June 6, 1990Date of Patent: May 26, 1992Assignee: Merck & Co., Inc.Inventors: Robert L. Smith, Wasyl Halczenko, George D. Hartman, Gerald E. Stokker, Edward S. Inamine, Otto D. Hensens, David R. Houck, Ta J. Lee
-
Patent number: 5087702Abstract: Fermentation of the microorganism Streptomyces sp. (MA6750) ATCC No. 55042 in the presence of the Angiotensin II (A II) receptor antagonist of the following structure: ##STR1## yields an analog having a shikimate sugar-like moiety attached to the tetrazole, the said analog which is also an A II antagonist useful in the treatment of hypertension and congestive heart failure and other indications known to respond to A II angatonists.Type: GrantFiled: January 30, 1991Date of Patent: February 11, 1992Assignee: Merck & Co., Inc.Inventors: Shieh-Shung T. Chen, Byron H. Arison, Raymond F. White, Edward S. Inamine
-
Patent number: 5070015Abstract: Incubation of 13-deoxy ivermectin aglycone with a species of B. subtilis and of S. griseus results in the production of 13-.beta. ivermectin monoglucopyranoside as the major product and of 5-.beta. ivermectin monoglucopyranoside as the minor product.Type: GrantFiled: October 15, 1990Date of Patent: December 3, 1991Assignee: Merck & Co., Inc.Inventors: Brian R. Petuch, Shieh-Shung T. Chen, Edward S. Inamine, Raymond F. White
-
Patent number: 4997755Abstract: A microbiological process is described for the preparation of 6-desmethyl-6-.beta.-hydroxymethyl and 6-desmethyl-6-.beta.-carboxylovastatin derivatives and 8-acyl analogs thereof.Type: GrantFiled: April 14, 1988Date of Patent: March 5, 1991Assignee: Merck & Co., Inc.Inventors: Joanne M. Williamson, David Houck, Edward S. Inamine
-
Patent number: 4981792Abstract: Described is a process for producing a new immunosuppressant, "demethomycin" (L-682,993) a C-31 demethylated analog of L-679,934 under novel fermentation conditions utilizing the microorganism, Actinoplanacete sp., (Merck Culture Collection MA 6559) ATCC No. 53771. The macrolide immunosuppressant is useful in prevent human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.Type: GrantFiled: June 29, 1988Date of Patent: January 1, 1991Assignee: Merck & Co., Inc.Inventors: Edward S. Inamine, Byron H. Arison, Shieh-Shung T. Chen, Linda S. Wicker
-
Patent number: 4975372Abstract: Described is a new immunosuppressant, L-685,487, a monodemethylated rearranged derivative of L-683,590, produced under fermentation conditions utilizing the microorganism, unidentified Actinomycete (Merck Cultrue Collection MA 6474) ATCC No. 53828. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.Type: GrantFiled: January 13, 1989Date of Patent: December 4, 1990Assignee: Merck & Co., Inc.Inventors: Byron H. Arison, Edward S. Inamine, Shieh-Shung T. Chen, Linda S. Wicker
-
Patent number: 4940727Abstract: Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors are useful as anti-hypercholesterolemic agents and are represented by the following general structural formulae (I) and (II): ##STR1##Type: GrantFiled: October 6, 1988Date of Patent: July 10, 1990Assignee: Merck & Co., Inc.Inventors: Edward S. Inamine, Otto D. Hensens, David R. Houck, Ta J. Lee, Robert L. Smith, Wasyl Halczenko, George D. Hartman, Gerald E. Stokker
-
Patent number: 4766112Abstract: There are disclosed macrolides isolated from the fermentation broth, with avermectin Bla, avermectin Blb or 22,23-dihydro avermectin Bla as a substrate, of a known microorganism identified as MA-6181. The structure of the novel compounds isolated from the microorganism are presented based upon analytical studies. The compounds are highly potent antiparasitic, insecticidal, and anthelmintic agents. Compositions for such uses are also disclosed.Type: GrantFiled: April 30, 1986Date of Patent: August 23, 1988Assignee: Merck & Co. Inc.Inventors: Robert T. Goegelman, Edward S. Inamine, Raymond F. White
-
Patent number: 4696925Abstract: Products of Aspergillus alliaceus fermentation having cholecystokinin (CCK) antagonist activity, their preparation and use are disclosed.Type: GrantFiled: January 25, 1985Date of Patent: September 29, 1987Assignee: Merck & Co., Inc.Inventors: David R. Houck, Edward S. Inamine, Michael A. Goetz
-
Patent number: 4668696Abstract: There is disclosed a macrolide isolated from the fermentation broth, with 22,23-dihydro avermectin Bla aglycone as a substrate, of a known microorganism identified as MA-5853. The structure of the novel compound isolated from the microorganism is presented based upon analytical studies. The compound is a highly potent antiparasitic, insecticidal, and anthelmintic agent. Compositions for such uses are also disclosed.Type: GrantFiled: July 29, 1985Date of Patent: May 26, 1987Assignee: Merck & Co., Inc.Inventors: Robert T. Goegelman, Raymond F. White, Edward S. Inamine
-
Patent number: 4666937Abstract: There are disclosed novel compounds which are derived from 22,23-dihydro avermectin Bla aglycone, 13-deoxy-22,23 dihydro overmectin Bla aglycone and 13-deoxy-22,23-dihydro overmectin Blb aglycone. The six compounds are hydroxy adducts of the substrate avermectin compound at the 12a, 24, 24a, 26, 26a and 27 positions. The hydroxy adducts are prepared by incubating the substrate with the microorganism Cunninghamella blakesleeana and isolating the hydroxy adducts from the fermentation broth. The compounds are highly potent antiparasitic, insecticidal and anthelmintic agents.Type: GrantFiled: February 20, 1986Date of Patent: May 19, 1987Assignee: Merck & Co., Inc.Inventors: Robert T. Goegelman, Edward S. Inamine, Raymond F. White
-
Patent number: RE36481Abstract: Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II): ##STR1##Type: GrantFiled: November 4, 1998Date of Patent: January 4, 2000Assignee: Merck & Co., Inc.Inventors: Edward S. Inamine, Otto D. Hensens, David R. Houck, Ta J. Lee, Robert L. Smith, Wasyl Halczenko, George D. Hartman, Gerald E. Stokker
-
Patent number: RE36520Abstract: Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors are useful as antihypercholesterolemic agents and are represented by the following general structural formula (II): ##STR1##Type: GrantFiled: November 4, 1998Date of Patent: January 18, 2000Assignee: Merck & Co., Inc.Inventors: Robert L. Smith, Wasyl Halczenko, George D. Hartman, Gerald E. Stokker, Edward S. Inamine, Otto D. Hensens, David R. Houck, Ta Jyh Lee